Список литературы

1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; Issue 1: 1–126
2. Смирнов А.В., Добронравов В.А., Румянцев А.Ш., Каюков И.Г. Острое повреждение почек. МИА, М., 2015: 488.
3. Zeng X, McMahon GM, Bates DW, Waikar SS. Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol 2014; 9(1):1220
4. Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Pract 2013; 2013:479730.
5. Hsu CY, McCulloch CE, Fan D et al. Community-based incidence of acute renal failure. Kidney Int 2007; 72: 208-212.
6. Piccinni P, Cruz DN, Gramaticopolo S, Garzotto F, Dal Santo M, Aneloni G, et al; NEFROINT investigators. Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT). Minerva Anestesiol 2011;77:1072–1083.
7. Lewington AJP, Cerda J, Mehta RL. Raising awareness of Acute Kidney Injury: A global perspective of a silent killer. Kidney Int 2013; 84(3): 457–467.
8. Chawla LS, Bellomo R, Bihorac A. et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017 Apr;13(4):241-257. doi: 10.1038/nrneph.2017.2
9. Mirnezami R., Nicholson J., Darzi A. Preparing for precision medicine./ N. Engl. J. Med. — 2012. — Vol. 366. — №6. — P. 489–491.
10. Смирнов А.В. Системный подход к анализу кардиоренальных взаимоотношений как первый шаг на пути к медицине формата П4. Нефрология 2011; 15 (2): 11–19.
11. Schumann GB, Greenberg NF. Usefulness of macroscopic urinalysis as a screening procedure. A preliminary report. Am J Clin Pathol. 1979; 71(4): 452-456.
12. Slocum JL, Heung M, Pennathur S. Marking renal injury: can we move beyond serum creatinine? Transl Res. 2012 Apr;159(4):277-89.
13. Смирнов АВ, Каюков ИГ, Дегтерева ОА и др. Проблемы диагностики и стратификации тяжести острого повреждения почек. Нефрология 2009; 13(3): 9-18.
14. Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 2009; 20(3):672-679.
15. Bouman C , KellumJ A, , Levin N. Definition of acute renal failure. Acute Dialysis Quality Initiative. 2nd International Consensus Conference, 2002; National Kidney Foundation KD: Clinical practice guidelines for chronic Kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002;39 [Suppl 1]: S1-S266.
16. Macedo E, Bouchard J, Soroko SH et al. Fluidh accumulation, recognition and staging of acute kidney injury in critically-ill patients. Crit Care 2010;14(3): R82.
17. Bouchard J, Macedo E, Soroko S, et al. Comparison of methods for estimating glomerular filtration rate in critically ill patients with acute kidney injury. Nephrology Dialysis Transplantation. 2010;25(1):102-107. doi:10.1093/ndt/gfp392
18. Jelliffe R. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am J Nephrol. 2002 Jul-Aug;22(4):320-324
19. Espinel CH. The FENa test. Use in the differential diagnosis of acute renal failure. JAMA. 1976;236(6):579-581.
20. Miller TR, Anderson RJ, Linas SL et al. Urinary diagnostic indices in acute renal failure: a prospective study. Ann Intern Med. 1978;89(1):47-50.
21. Nanji AJ. Increased fractional excretion of sodium in prerenal azotemia: need for careful interpretation. Clin Chem. 1981;27(7):1314-1315.
22. Tsigou E, Psallida V, Demponeras C, et al. Role of new biomarkers: functional and structural damage. Crit Care Res Pract. 2013;2013:361078.
23. Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant. 2013;28(2):254-273.
24. Koyner JL, Vaidya VS, Bennett MR Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol. 2010;5(12):2154-1265.
25. Matsui K1, Kamijo-Ikemori A, Hara M et al. Clinical significance of tubular and podocyte biomarkers in acute kidney injury. Clin Exp Nephrol. 2011;15(2):220-225.
26. Endre ZH, Pickering JW, Walker RJ et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int. 2011 May;79(10):1119-11130
27. Siew ED, Ikizler TA, Gebretsadik T et al. Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes. Clin J Am Soc Nephrol. 2010;5(8):1497-1505.
28. Vijayan A, Faubel S, Askenazi DJ et al. Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment. Am J Kidney Dis. 2016 Jul;68(1):1928. doi: 10.1053/j.ajkd.2015.12.033
29. Каюков И.Г., Смирнов А.В., Эммануэль В.Л. Цистатин С в современной медицине. Нефрология. 2012. 16(1): 22-39.
30. Nickolas TL1, Schmidt-Ott KM, Canetta P et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol. 2012; 59(3):246-255.
31. Schneider A, Johnson L, Goodwin M et al. Bench-to-bedside review: contrast enhanced ultrasonography--a promising technique to assess renal perfusion in the ICU. Crit Care. 2011;15(3):157.
32. Moghazi S, Jones E, Schroepple J et al. Correlation of renal histopathology with sonographic findings. Kidney Int. 2005;67(4):1515-1520.
33. Platt JF, Rubin JM, Ellis JH. Acute renal failure: possible role of duplex Doppler US in distinction between acute prerenal failure and acute tubular necrosis. Radiology. 1991;179(2):419-423.
34. Kalantarinia K. Novel imaging techniques in acute kidney injury. Curr Drug Targets. 2009;10(12):1184-1189.
35. Tublin ME, Bude RO, Platt JF. Review. The resistive index in renal Doppler sonography: where do we stand? AJR Am J Roentgenol. 2003;180(4):885-892.
36. Фомина С.В., Завадовская В.Д. , Юсубов М.С. и др. Контрастные препараты для ультразвукового исследования. Бюллетень сибирской медицины 2011; (6): 137-142;
37. Зубарев А.В., Фёдорова А.А., Чернышев В.В. и др. Применение эхоконтрастных препаратов в клинике и перспективы синхронизации УЗИ, КТи МРТ-изображений (собственный опыт и обзор литературы). Медицинская Визуализация 2015; (1): 94-114
38. Romero JR, Frey JL, Schwamm LH et al. Cerebral ischemic events associated with 'bubble study' for identification of right to left shunts. Stroke. 2009;40(7):2343-2348.
39. Schneider A, Johnson L, Goodwin M et al. Bench-to-bedside review: contrast enhanced ultrasonography--a promising technique to assess renal perfusion in the ICU. Crit Care. 2011;15(3):157.
40. Fuiano G. et al. Current indications for renal biopsy: A questionnaire-based survey. American Journal of Kidney Diseases , Volume 35 , Issue 3 , 448 457
41. Rivera F, Lopez-Gomez JM, Perez-Garcia R et al. Clinicopathologic correlations of renal pathology in Spain. Kidney Int. 2004;66(3):898-904.
42. Lopez-Gomez JM, Rivera F et al. Renal biopsy findings in acute renal failure in the cohort of patients in the Spanish Registry of Glomerulonephritis. Clin J Am Soc Nephrol. 2008;3(3):674-681.
43. Himmelfarb J, Joannidis M, Molitoris B, Schietz M, Okusa MD, Warnock D, Laghi F, Goldstein SL, Prielipp R, Parikh CR, Pannu N, Lobo SM, Shah S, D’Intini V, Kellum JA (2008) Evaluation and in-itial management of acute kidney injury. Clin J Am Soc Nephrol 3:962–967
44. Rhodes A, Evans LE, Alhazzani W. et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017; 43:304–377
45. Prowle JR, Kirwan CJ, Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. Nat Rev Nephrol 2014; 10:37–47
46. Ostermann M, Straaten HM, Forni LG. Fluid overload and acute kidney injury: cause or consequence? Crit Care 2015; 19:443
47. Kellum JA, Chawla LS, Keener C. et al. The effects of alternative resuscitation strategies on acute kidney injury in patients with septic shock. Am J Respir Crit Care Med 2016; 193:281–287
48. Chowdhury AH, Cox EF, Francis ST, Lobo DN. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and Plasma lyte 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg 2012; 256:18–24
49. Wilkes NJ, Woolf R, Mutch M. et al. The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. Anesth Analg 2001; 93:811–816
50. Alphonsus CS, Rodseth RN. The endothelial glycocalyx: a review of the vascular barrier. Anaesthesia 2014; 69:777–784
51. Chappell D, Jacob M. Role of the glycocalyx in fluid manage‐ ment: small things matter. Best Pract Res Clin Anaesthesiol 2014; 28:227–234
52. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P (1996) Effect of hydroxyethylstarch in brain‐dead kidney donors on renal func‐ tion in kidney‐transplant recipients. Lancet 348:1620–1622
53. Perner A., Haase N., Guttormsen A.B. et al.Hydroxyethylstarch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 2003; 367:124–134.
54. Moeller C, Fleischmann C, Thomas-Rueddel D, Vlasakov V, Rochwerg B, Theurer P, Gattinoni L, Reinhart K, Hartog CS. How safe is gelatin? A systematic review and metaanalysis of gelatin-containing plasma expanders vs crystalloids and albumin. J Crit Care. 2016 Oct;35:75-83. doi: 10.1016/j.jcrc.2016.04.011.
55. Caironi P., Tognoni G., Masson S. et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370:1412–1421
56. Schortgen F, Lacherade JC, Bruneel F. et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357:911–916
57. Mardel SN, Saunders FM, Allen H. et al. Reduced quality of clot formation with gelatinbased plasma substitutes. Br J Anaesth 1998; 80:204–207
58. Laxenaire MC, Charpentier C, Feldman L. Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study. Ann Fr Anesth Reanim 1994; 13:301–310
59. Fliser D, Zurbruggen I, Mutschler E. et al. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int 1999; 55:629–634
60. Wiedermann CJ, Dunzendorfer S, Gaioni LU, Zaraca F, Joannidis M (2010) Hyperoncotic colloids and acute kidney injury: a meta‐analysis of randomized trials. Crit Care 14:R191
61. Inoue M., Okajima K., Itoh K. et al. Mechanism of furosemide resistance in analbumine‐ mic rats and hypoalbuminemic patients. Kidney Int 1987; 32 (2):198–203.
62. Wiedermann C.J., Dunzendorfer S., Gaioni L.U. et al.Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care 2010; 149(5):R191.
63. Kellum JA, Lameire N, KDIGO AKI Guideline Work Group (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17:204
64. Young P, Bailey M, Beasley R, Henderson S, Mackle D, McArthur C, McGuinness S, Mehrtens J, Myburgh J, Psirides A, Reddy S, Bellomo R (2015) Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. JAMA 314:1701–1710
65. Joannidis M, Forni LG. Acute kidney injury: buffered crystalloids or saline in the ICU—a SPLIT decision. Nat Rev Nephrol 2016; 12:6–8
66. Semler MW, Wanderer JP, Ehrenfeld JM. Balanced crystalloids versus saline in the intensive care unit: the SALT randomized trial. Am J Respir Crit Care Med. 2017 May 15;195(10):1362-1372. doi: 10.1164/rccm.201607-1345OC
67. McGuinness S.P., Parke R.L., Bellomo R. et al. Sodium bicarbonate infusion to reduce cardiac surgery-associated acute kidney injury: a phase II multicenter double-blind randomized controlled trial. Crit Care Med 2013; 41:1599–1607.
68. Kristeller J.L, Zavorsky G.S., Prior J.E. et al. Lack of effectiveness of sodium bicar‐ bonate in preventing kidney injury in patients undergoing cardiac surgery: a randomized controlled trial. Pharmacotherapy 2013; 33:710–717.
69. Haase M, Haase-Fielitz A, Bellomo R. et al. Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med 2009; 37:39–47
70. Tie HT, Luo MZ, Luo MJ. Et al. Sodium bicarbonate in the prevention of cardiac surgery-associated acute kidney injury: a systematic review and meta-analysis. Crit Care 2014; 18:517
71. Tian ML, Hu Y, Yuan J, Zha Y. Efficacy and safety of perioperative sodium bicarbonate therapy for cardiac surgery-associated acute kidney injury: a meta-analysis. J Cardiovasc Pharmacol 2015; 65:130–136
72. Kim JH, Kim HJ, Kim JY. et al. Meta-analysis of sodium bicarbonate therapy for prevention of cardiac surgery-associated acute kidney injury. J Cardiothorac Vasc Anesth 2015; 29:1248–1256
73. Bailey M, McGuinness S, Haase M, Haase‐Fielitz A, Parke R, Hodgson CL, Forbes A, Bagshaw SM, Bellomo R (2015) Sodium bicarbonate and renal function after cardiac surgery: a prospectively planned individual patient meta‐analysis. Anesthesiology 122:294–306
74. De Backer D., Biston P., Devriendt J. et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779–789.
75. Qureshi A.I., Palesch Y.Y., Suarez J.I. Intensive blood‐pressure lowering in cerebral hemorrhage. N Eng J Med 2016; 375:e48.
76. Serpa Neto A., Nassar A.P., Cardoso S.O. et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care 2012; 16:R154.
77. Bragadottir G., Redfors B., Nygren A. et al. Low‐dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post‐cardiac surgery patients. Acta AnaesthesiolScand2009; 53:1052–1059.
78. Ramaswamy D., Corrigan G., Polhemus C. et al. Maintenance and recovery stages of postischemic acute renal failure in humans. Am J Physiol Renal Physiol2002; 282:F271–F280.
79. Conger J., Robinette J., Villar A. et al. Increased nitric oxide synthase activity despite lack of response to endothelium‐ dependent vasodilators in postischemic acute renal failure in rats. J Clin Invest 1995; 96:631–638.
80. Wan L., Bagshaw S.M., Langenberg C. et al. Pathophysiology of septic acute kidney injury: what do we really know? Crit Care Med 2008; 36:S198–S203.
81. Ishikawa K., May C.N., Gobe G. et al. Pathophysiology of septic acute kidney injury: a different view of tubular injury. ContribNephrol2010; 165:18–27.
82. Legrand M., Bezemer R., Kandil A. et al. The role of renal hypoperfusion in development of renal microcirculatory dysfunction in endotoxemic rats. Intensive Care Med 2011; 37:1534–1542.
83. Molitoris B.A., Sutton T.A. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int 2004; 66:496–499.
84. Lauschke A, Teichgraber UKM, Frei U, Eckardt KU (2006) ‘Low‐dose’ dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 69:1669–1674
85. Friedrich JO, Adhikari N, Herridge MS, Beyene J (2005) Meta‐analysis: low‐dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 142:510–524
86. Karthik S, Lisbon A (2006) Low‐dose dopamine in the intensive care unit. Semin Dial 19:465–471
87. Luo C, Yuan D, Li X. et al. Propofol attenuated acute kidney injury after orthotopic liver transplantation via inhibiting gap junction composed of connexin 32. Anesthesiology 2015; 122:72–86
88. Hsing CH, Chou W, Wang JJ. et al. Propofol increases bone morphogenetic protein-7 and decreases oxidative stress in sepsis-induced acute kidney injury. Nephrol Dial Transplant 2011; 26:1162–1172
89. Villela NR, Nascimento Junior P. et al. Effects of dexmedetomidine on renal system and on vasopressin plasma levels. Experimental study in dogs. Rev Bras Anestesiol 2005; 55:429–440
90. Billings FT, Chen SW, Kim M. et al. Alpha2-adrenergic agonists protect against radiocontrastinduced nephropathy in mice. Am J Physiol Renal Physiol 2008; 295:F741–748
91. Hsing CH, Lin CF, So E. et al. Alpha2-adrenoceptor agonist dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5. Am J Physiol Renal Physiol 2012; 303:F1443–F1453
92. Tan F, Chen Y, Yuan D. et al. Dexmedetomidine protects against acute kidney injury through downregulating inflammatory reactions in endotoxemia rats. Biomed Rep 2015; 3:365–370
93. Yao H, Chi X, Jin Y. et al. Dexmedetomidine inhibits TLR4/NF-kappaB activation and reduces acute kidney injury after orthotopic autologous liver transplantation in rats. Sci Rep 2015; 5:16849
94. Reade MC, Finfer S Sedation and delirium in the intensive care unit. N Engl J Med 2014; 370:444– 454
95. Mirrakhimov AE, Voore P, Halytskyy O. et al. Propofol infusion syndrome in adults: a clinical update. Crit Care Res Pract 2015:260385
96. Krajcova A, Waldauf P, Andel M, Duska F Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit Care 2015; 19:398
97. Cremer OL, Moons KG, Bouman EA. et al. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001; 357:117–118
98. Leite TT, Macedo E, Martins Ida S. et al. Renal outcomes in critically ill patients receiving propofol or midazolam. Clin J Am Soc Nephrol 2015; 10:1937–1945
99. Yoo YC, Shim JK, Song Y. et al. Anesthetics influence the incidence of acute kidney injury following valvular heart surgery. Kidney Int 2014; 86:414–422
100. Pichot C, Longrois D, Ghignone M, Quintin L Dexmedetomidine and clonidine: a review of their pharmacodynamy to define their role for sedation in intensive care patients. Ann Fr Anesth Reanim 2012; 31:876–896
101. Leino K, Hynynen M, Jalonen J. et al. Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study. BMC Anesthesiol 2011; 11:9
102. Balkanay OO, Goksedef D, Omeroglu SN, Ipek G The dose-related effects of dexmedetomidine on renal functions and serum neutrophil gelatinase-associated lipocalin values after coronary artery bypass grafting: a randomized, triple-blind, placebo-controlled study. Interact Cardiovasc Thorac Surg 2015; 20:209–214
103. Cho JS, Shim JK, Soh S. et al. Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. Kidney Int 2016 89:693–700
104. Evans K. J., Greenberg A. Hyperkalemia: a review. J Intensive Care Med 2005; 20(5): 272290
105. Umpierrez GE, Isaacs SD, Bazargan N. et al. Hyperglycemia: an independent marker of inhospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87:978–982
106. Krinsley JS Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78:1471–1478
107. Van den Berghe G, Wouters P, Weekers F. et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359–1367
108. Van den Berghe G, Wilmer A, Hermans G. et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449–461
109. Whitlock RP, Devereaux PJ, Teoh KH. et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386:1243–1253
110. Jacob K.A., Leaf D.E., Dieleman J.M. et al. Dexamethasone for Cardiac Surgery Study Group Intraoperative high-dose dexamethasone and severe AKI after cardiac surgery. J Am Soc Nephrol 2015; 26:2947–2951.
111. Song YR, Lee T, You SJ. et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009; 30:253–260
112. de Seigneux S, Ponte B, Weiss L. et al. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 2012; 13:132
113. Yoo YC, Shim JK, Kim JC. et al. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011; 115:929–937
114. Kim JH, Shim JK, Song JW. et al. Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. Crit Care 2013; 17:R254
115. Tasanarong A, Duangchana S, Sumransurp S. et al. Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial. BMC Nephrol 2013; 14:136
116. Tie HT, Luo MZ, Lin D. et al. Erythropoietin administration for prevention of cardiac surgery-associated acute kidney injury: a meta-analysis of randomized controlled trials. Eur J Cardiothorac Surg 2015; 48:32–39
117. Penny-Dimri JC, Cochrane AD, Perry LA, Smith JA. Characterising the role of perioperative erythropoietin for preventing acute kidney injury after cardiac surgery: systematic review and meta-analysis. Heart Lung Circ (2016) 25:1067–1076
118. Dardashti A, Ederoth P, Algotsson L. et al. Erythropoietin and protection of renal function in cardiac surgery (the EPRICS Trial). Anesthesiology 2014; 121:582–590
119. Zhao C, Lin Z, Luo Q, et al. Efficacy and safety of erythropoietin to prevent acute kidney injury in patients with critical illness or perioperative care: a systematic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol 2015; 65:593–600
120. Kim JE, Song SW, Kim JY. et al. Effect of a single bolus of erythropoietin on renoprotection in patients undergoing thoracic aortic surgery with moderate hypothermic circulatory arrest. Ann Thorac Surg 2016; 101:690–696
121. Shema-Didi L, Kristal B, Eizenberg S.et al. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: a randomized controlled trial. Nephrology (Carlton) 2016; 21:295–300
122. Pons M, Plante I, LeBrun M et al. Protein-rich diet attenuates cycloporin A-induced renal tubular damage in rats. J Ren Nutr 2003; 13:84–92
123. Heyland DK, Elke G, Cook D. et al. Glutamine and antioxidants in the critically ill patient: a post hoc analysis of a large-scale randomized trial. JPEN J Parenter Enteral Nutr 2015; 39:401–409
124. Mitchell JR, Verweij M, Brand K. et al. Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice. Aging Cell 2010; 9:40–53
125. Doig GS, Simpson F, Bellomo R. et al. Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial. Intensive Care Med 2015 41:1197–1208
126. Gunst J, Vanhorebeek I, Casaer MP. Et al. Impact of early parenteral nutrition on metabolism and kidney injury. J Am Soc Nephrol 2013; 24:995–1005
127. Al-Dorzi HM, Albarrak A, Ferwana M. et al. Lower versus higher dose of enteral caloric intake in adult critically ill patients: a systematic review and meta-analysis. Crit Care 2016; 20:358
128. Gonzales DA, Norsworthy KJ, Kern SJ. et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 2007; 5:32
129. Zhao SJ, Zhong ZS, Qi GX et al. The efficacy of N-acetylcysteine plus sodium bicarbonate in the prevention of contrast-induced nephropathy after cardiac catheterization and percutaneous coronary intervention: a meta‐analysis of randomized controlled trials. Int J Cardiol 2016;221:251–259
130. Wang N, Qian P, Kumar S. et al. The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: a systematic review and trial sequential analysis. Int J Cardiol 2016; 209:319–327
131. Kang X, Hu DY, Li CB. Et al. N-acetylcysteine for the prevention of contrastinduced nephropathy in patients with preexisting renal insufficiency or diabetes: a systematic review and meta-analysis. Ren Fail 2015; 37(10):297–303
132. Sun Z, Fu Q, Cao L. et al. Intravenous N-acetylcysteine for prevention of contrastinduced nephropathy: a metaanalysis of randomized, controlled trials. PLoS One 2013; 8:e55124
133. Guo Z, Liu J, Lei L, Xue Y, Liu L, Huang H, Chen S, Liu Y, Lin Y, Tao J, Xu Q, Wu K, Zhang L, Chen JY. Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2020 Oct 16;10(10):e039009. doi: 10.1136/bmjopen-2020-039009. PMID: 33067289; PMCID: PMC7569944.
134. Burns KE, Chu MW, Novick RJ. et al. Perioperative N‐acetylcysteine to prevent renal dysfunction in high‐risk patients undergoing CABG surgery: a randomized controlled trial. JAMA 2005; 294:342–350
135. Macedo E, Abdulkader R, Castro I. et al. Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair a randomized controlled trial. Nephrol Dial Transplant 2006; 21:1863–1869
136. Komisarof JA, Gilkey GM, Peters DM. et al. N-acetylcysteine for patients with prolonged hypotension as prophylaxis for acute renal failure (NEPHRON). Crit Care Med 2007; 35:435–441
137. Sisillo E, Ceriani R, Bortone F et al. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. Crit Care Med 2008; 36:81–86
138. Adabag AS, Ishani A, Koneswaran S. et al. Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: a randomized controlled trial. Am Heart J 2008; 155:1143–1149
139. Song JW, Shim JK, Soh S. et al. Double-blinded, randomized controlled trial of Nacetylcysteine for prevention of acute kidney injury in high risk patients undergoing offpump coronary artery bypass. Nephrology (Carlton) 2015) 20:96–102
140. Wijeysundera DN, Beattie WS, Rao V. et al. N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. Can J Anaesth 2007; 54:872–881
141. Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila) 2009; 47:81–88
142. Molnar Z, Shearer E, Lowe D N-Acetylcysteine treatment to prevent the progression of multisystem organ failure: a prospective, randomized, placebo‐controlled study. Crit Care Med 1999; 27:1100–1104
143. Peake SL, Moran JL, Leppard PI. N-acetylcysteine depresses cardiac performance in patients with septic shock. Crit Care Med 1996; 24:1302–1310
144. Angstwurm MW, Engelmann L, Zimmermann T. et al. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple‐center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 2007; 35:118–126
145. Bloos F, Trips E, Nierhaus A. et al. Effect of sodium selenite administration and procalcitonin‐guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA intern med 2016; 176: 1266-1276
146. Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotropic effects of statins. Indian J Endocrinol Metab 2015; 19:554–562
147. Han Y, Zhu G, Han L. et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 2014; 63:62–70
148. Leoncini M, Toso A, Maioli M. et al. Early high-dose rosuvastatin for contrastinduced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective EFFECT of Rosuvastatin and Antiplatelet Therapy On contrastinduced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol 2014; 63:71–79
149. Quintavalle C, Fiore D, De Micco F. et al. Impact of a high loading dose of atorvastatin on contrast‐induced acute kidney injury. Circulation 2012; 126:3008–3016
150. Lee JM, Park J, Jeon KH. Et al. Efficacy of short-term high-dose statin pretreatment in prevention of contrast-induced acute kidney injury: updated study level meta-analysis of 13 randomized controlled trials. PLoS One 2014; 9:e111397
151. Ukaigwe A, Karmacharya P, Mahmood M. et al. Meta‐analysis on efficacy of statins for prevention of contrast‐induced acute kidney injury in patients undergoing coronary angiography. Am J Cardiol 2014); 14:1295–1302
152. Singh N, Lee JZ, Huang JJ. et al. Benefit of statin pretreatment in prevention of contrastinduced nephropathy in different adult patient population: systematic review and metaanalysis. Open Heart 2014; 1:e000127
153. Marenzi G, Cosentino N, Werba JP. Et al. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol 2015; 183:47–53
154. Liakopoulos OJ, Choi YH, Haldenwang PL. et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a metaanalysis of over 30,000 patients. Eur Heart J 2008; 29:1548–1559
155. Wang J, Gu C, Gao M. et al. Preoperative statin therapy and renal outcomes after cardiac surgery: a meta-analysis and meta-regression of 59,771 patients. Can J Cardiol 2015; 31:1051–1060
156. Billings FT, Hendricks PA, Schildcrout JS. et al. High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: a randomized clinical trial. JAMA 2016; 315:877–888
157. Park JH, Shim JK, Song JW. Et al. Effect of atorvastatin on the incidence of acute kidney injury following valvular heart surgery: a randomized, placebo-controlled trial. Intensive Care Med 2016; 42:1398–1407
158. Zheng Z, Jayaram R, Jiang L. et al. Perioperative rosuvastatin in cardiac surgery. N Engl J Med 2016; 374:1744–1753
159. Ho KM, Power BM. Benefits and risks of furosemide in acute kidney injury. Anaesthesia. 2010; 65(3):283-293.
160. Weisbord SD, Palevsky PM. Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol. 2008 Jan;3(1):273-280.
161. McCullough PA. Multimodality prevention of contrast-induced acute kidney injury. Am J Kidney Dis. 2008;51(2):169-172.
162. Solomon R., Werner C., Mann D. et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331:1416–1420.
163. Mueller C., Buerkle G., Buettner H.J. et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162:329–336.
164. Merten G.J., Burgess W.P., Gray L.V. et al. Prevention of contrast‐induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291:2328–2334.
165. Ozcan E.E., Guneri S., Akdeniz B. et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J 2007; 154:539–544.
166. Briguori C., Airoldi F., D’Andrea D. et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007; 115:1211–1217.
167. Newhouse J.H., Kho D., Rao Q.A., Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. Am J Roentgenol 2008; 191:376–382.
168. Hoste E.A., Doom S., De Waele J. et al. Epidemiology of contrast-associated acute kidney injury in ICU patients: a retrospective cohort analysis. Intensive Care Med 2011; 37:1921–1931.
169. Cely C.M., Schein R.M., Quartin A.A. Risk of contrast induced nephropathy in the critically ill: a prospective, case matched study. Crit Care 2012; 16:R67.
170. Ehrmann S., Badin J., Savath L. et al. Acute kidney injury in the critically ill: is iodinated contrast medium really harmful? Crit Care Med 2013; 41:1017–1026.
171. McDonald J.S., McDonald R.J., Williamson E.E. et al. Post‐contrast acute kidney injury in intensive care unit patients: a propensity score‐adjusted study. Intensive Care Med 2017; 43(6): 774-784.
172. Ehrmann S., Quartin A., Hobbs B.P. et al. Contrast‐associated acute kidney injury in the critically ill: systematic review and Bayesian meta‐analysis. Intensive Care Med 2017; 43(6): 785-794.
173. Al-Ani A1, Al-Jalham K, Ibrahim T et al. Factors determining renal impairment in unilateral ureteral colic secondary to calcular disease: a prospective study. Int Urol Nephrol. 2015; 47(7):1085-1090.
174. Rosenzweig B, Pinthus JH, Kleinmann N et al. The relative contribution of urine extravasation to elevate plasma creatinine levels in acute unilateral ureteral obstruction. Can Urol Assoc J. 2015; 9(7-8):E428-433.
175. Wang A.Y., Bellomo R. Renal replacement therapy in the ECU: intermittent hemodialysis, sustained low-efficiency dialysis or continuous renal replacement therapy? Curr Opin Crit Care 2018; 24: 437-44.2
176. Bagshaw SM, Uchino S, Bellomo R et al. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. J Crit Care. 2009;24(1):129-140.
177. Gibney NI, Hoste E, Burdmann EA et al. Timing of initiation and discontinuation of renal replacement therapy in AKI: unanswered key questions. Clin J Am Soc Nephrol 2008;3(3):876-880.
178. Thakar CV, Christianson A, Almenoff P et al. Degree of acute kidney injury before dialysis initiation and hospital mortality in critically ill patients. Int J Nephrol 2013; 2013: 827459.
179. Annigeri RA, Ostermann M, Tolwani A, et al. Renal Support for Acute Kidney Injury in the Developing World. Kidney International Reports 2017; №2: 559–578
180. Karvellas C.J., Farhat M.R., Sajjad I. et al. A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. Critical Care. 2011; №15: 72.
181. Wald R, Adhikari NK, Smith OM, et al. Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury. Kidney Int. 2015; №88(4): 897-904.
182. Zarbock A, Kellum JA, Schmidt C, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA 2016; №315(20): 2190-9
183. Gaudry S, Hajage D, Schortgen F, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016; №375(2): 122-33.
184. Xiao-mei Yang, Guo-wei Tu, Ji-li Zheng, et al. A comparison of early versus late initiation of renal replacement therapy for acute kidney injury in critically ill patients: an updated systematic review and metaanalysis of randomized controlled trials. BMC Nephrology 2017; №18: 264
185. Clark E, Wald R, Levin A, et al. Timing the initiation of renal replacement therapy for acute kidney injury in Canadian intensive care units: a multicentre observational study. Can J Anaesth.2012; №59 (9): 861-70
186. Ostermann M, Joannidis M, Pani A, et al. Patient Selection and Timing of Continuous Renal Replacement Therapy. 17th Acute Disease Quality Initiative (ADQI) Consensus Group. Blood Purif. 2016; 42(3): 224-37
187. Bagshaw S.M., Berthiaume L.R., Delaney A. et al. Continuous versus intermittent renal re-placement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med. 2008; №36: 610–617.
188. Ghahramani N., Shadrou S., Hollenbeak C. A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure. Nephrol (Carlton). 2008; №13: 570-578.
189. Rabindranath K., Adams J., Macleod A.M. et al. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev. 2007; №18: CD003773
190. Nash DM, Przech S, Wald R et al. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. J Crit Care. 2017;№41: 138-144
191. Zhang L, Yang J, Eastwood GM, et al. Extended Daily Dialysis Versus Continuous Renal Replacement Therapy for Acute Kidney Injury: A Meta-analysis. Am J Kidney Dis 2015; 66 (2): 322-330.
192. Schneider AG, Bellomo R, Bagshaw SM, et al. Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and metaanalysis. Intensive Care Med. 2013; №39 (6): 987-97.
193. Liang KV, Sileanu FE, Clermont G et al. Modality of RRT and Recovery of Kidney Function after AKI in Patients Surviving to Hospital Discharge. Clin J Am Soc Nephrol. 2016; №11 (1): 30-8.
194. Schoenfelder T, Chen X, Bleß H-H. Effects of continuous and intermittent renal replacement therapies among adult patients with acute kidney injury. GMS Health Technology Assessment. 2017;13:Doc01. doi:10.3205/hta000127.
195. Friedrich J.O., Wald R., Bagshaw S.M. et al. Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis. Critical Care. 2012; №16: R146
196. Ronco C, Ricci Z, De Backer D. et al. Renal replacement therapy in acute kidney injury: controversy and consensus. Crit Care. 2015; (19): 146.
197. Ricci Z, Ronco C. Preversus post-dilution CVVH. Blood Purif 2005; (23): 338.
198. Tian JH, Ma B, Yang K, et al. Bicarbonateversus lactate-buffered solutions for acute continuous haemodiafiltration or haemofiltration. Cochrane Database Syst Rev. 2015; №5 (3): CD006819
199. Doi K., Nishida O., Shigematsu T. et al. The Japanese Clinical Practice Guideline for acute kidney injury 2016. J Intensive Care 2018; 6:48
200. Tonelli M., Manns B., Feller-Kopman D. Acute renal failure in the intensive care unit: a systematic review of the impact of dialytic modality on mortality and renal recovery. Am J Kidney Dis 2002; 40: 875-885.
201. Pannu N., Klarenbach S., Wiebe N. et al. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA 2008; 299: 793-805.
202. Bagshaw S.M., Berthiaume L.R., Delaney A., Bellomo R. Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. Crit Care Med 2008; 36: 610-617
203. Gasparovic V, Filipovic-Grcic I, Merkler M, Pisl Z. Continuous renal replacement therapy (CRRT) or intermittent hemodialysis (IHD) – what is the procedure of choice in critically ill patients? Ren Fail. 2003;25:855–862 ;
204. Kaizu K, Inada Y, Kawamura A et al. Current status of blood purification in critical care in Japan. Contrib Nephrol. 2010;166:4–10;
205. Vanholder R, Van Biesen W, Hoste E, Lameire N. Pro/con debate: continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish? Crit Care. 2011;15:204
206. Полушин Ю.С., Соколов Д.В., Белоусов Д.Ю., Чеберда А.Е. Фармакоэкономическая оценка интермиттирующей и продолжительной заместительной почечной терапии. Вестник анестезиологии и реаниматологии. 2017; 14(6):6-20.
207. Nash D.M., Przech S., Wald R., O’Reilly D. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. J Crit Care 2017; 41: 138-144
208. Liu L., Zhang L., LiuG.J., Fu P. Peritoneal dialysis for acute kidney injury. Cochrane database for systematic reviews. 2017; 12: Art. No.: CD011457.
209. Al-Hwiesh A., Abdul-Rahman I., Finkelstein F. et al. Acute kidney injury in critically ill patients: a prospective randomized study of tidal peritoneal dialysis versus continuous renal replacement therapy. Ther Apher Dial 2018; doi: 10.1111/1744-9987.12660. [Epub ahead of print]
210. Hutchison C.A., Cockwell P., Moroz V. etal. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomized controlled trial. Lancet Haematol 2019; 6(4): e217-e228
211. Bridoux F., Carron P.L., Pegourie B. et al. Effect of high cut-off hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy. A randomized clinical trial. JAMA 2017; 318: 2099–2110
212. Pasquali S., Iannuzzella F., Corrandini M. Et al. A novel option for reducing free light chains in myeloma kidney: Supra-hemodiafiltration with endogenous reinfusion (HFR). J Nephrol 2015; 28 (2): 251-254.
213. Pendon-Ruiz de Mier M.V., Alvarez-Lara M.A., Ojeda-López R. et al. Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure. Nefrologia 2013; 33 (6): 788-796.
214. Mene P., Giammarioli E., Fofi C. et al. Serum free light chains removal by HFR hemodiafiltration in patients with multiple myeloma and acute kidney injury: a case series. Kidney Blood Press Res 2018; 43 (4): 1263-1272.3-5
215. Leung N., Gertz M.A., Zeldenrust S.R et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008; 73:1282–1288
216. Premusic V., Batinic J., Roncevic P. et al. Role of plasmapheresis in the management of acute renal injury in patients with multiple myeloma: should we abandon it? Ther Apher Dial 2018; 22(1): 79-86
217. European Best Practice Guidelines for Haemodialysis (Part 1). V. Chronic intermittent hae-modialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant 2002; 17 (Suppl 7):63-71.
218. Lim W., Cook D.J., Crowther M.A. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004; 15:3192–3206
219. Bellomo R., Cass A., Cole L., et al. Intensity of continuous renal replacement therapy in critically ill patients. N Engl J Med 2009; 361:1627-1638.
220. Oliver M.J, Edwards L.J., Treleaven D.J. et al. Randomized study of temporary hemodialysis catheters. Int J Artif Organs 2002; 25: 40–44.
221. Ahmad S, Callan R, Cole JJ, Blagg CR. Dialysate made from dry chemicals using citrate acid increases dialysis dose. Am J Kidney Dis 2000; 35(3):493–499.
222. Kossmann RJ, Gonzales A, Callan R, Ahmad S. Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol. 2009; 4(9):1459–1464.
223. Faguer S., Saint-Cricq M., Nogie M-B. et al. Heparin-free prolonged intermittent hemodialysis using calcium-free citrate dialysate in critically ill patients. Crit Care Med 2017; 45(11): 1887-1892
224. Gabutti L, Lucchini B, Marone C, Alberio L, Burnier M. Citratevs. acetate-based dialysate in bicarbonate haemodialysis: Consequences on haemodynamics, coagulation, acidbase status, and electrolytes. BMC Nephrol. 2009; 10:7
225. Hanevold C., Lu S., Yonekawa K. Utility of citrate dialysate in management of acute kidney injury in children. Hemodial Int 2010; 14 [Suppl 1]: S2-S6
226. Palevsky P.M., Zhang J.H., O’Connor T.Z. et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359:7-20.
227. Ash S.R. Fluid mechanics and clinical success of central venous catheters for dialysis— answers to simple but persisting problems.Semin Dial 2007; 20(3):237-256
228. Huriaux L., Costille P., Quintard H. et al. Haemodialysis catheters in the intensive care unit. AnaesthCritCarePain Med 2017; 36(5): 313-319
229. Mrozek N., Lautrette A., Timsit J-F., Souweine B. How to deal with dialysis catheters in the ICU setting. AnnIntensive Care 2012;2(1):48
230. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: vascular access. Am J KidneyDis 2006; 48: S176–S307
231. O’Grady N.P., Alexander M., Dellinger E.P. et al. Guidelines for the prevention of intravas-cular catheter-related infections. Infect Control Hosp Epidemiol 2002; 23: 759–769.
232. Cimochowski G.E., Worley E., Rutherford W.E. et al. Superiority of the internal jugular over the subclavian access for temporary dialysis. Nephron 1990; 54: 154–161.
233. Schillinger F., Schillinger D., Montagnac R. et al. Post catheterisation vein stenosis in hae-modialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. Nephrol Dial Transplant 1991; 6: 722–724.
234. Agarwal A.K., Patel B.M., Haddad N.J. Central vein stenosis: a nephrologist’s perspective. Semin Dial 2007; 20: 53–62.
235. Pronovost P. Interventions to decrease catheter-related bloodstream infections in the ICU: the Keystone Intensive Care Unit Project. Am J Infect Control 2008; 36(10): S171.e1–5.
236. Hryszko T., Brzosko S., Mazerska M., et al. Risk factors of non tunneled non cuffed hemodialysis catheter malfunction. A prospective study. Nephron Clin Pract 2004; 96: c43–47.
237. Liangos O., Rao M., Ruthazer R. et al. Factors associated with urea reduction ratio in acute renal failure. Artif Organs 2004; 28: 1076–1081.
238. Naumovic R.T., Jovanovic D.B., Djukanovic L.J. Temporary vascular catheters for hemodialysis: a 3-year prospective study. Int J Artif Organs 2004; 27: 848–854.
239. Leblanc M., Fedak S., Mokris G. et al. Blood recirculation in temporary central catheters for acute hemodialysis. Clin Nephrol 1996; 45: 315–319
240. Little M.A., Conlon P.J., Walshe J.J. Access recirculation in temporary hemodialysis catheters as measured by the saline dilution technique. Am J Kidney Dis 2000; 36: 1135– 1139.
241. Marschall J., Mermel L.A., Classen D. et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 (Suppl 1): S22–30.
242. Pratt R.J., Pellowe C.M., Wilson J.A. et al. National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect 2007; 65 (Suppl 1): S1–64.
243. Kusminsky R.E. Complications of central venous catheterization. J Am Coll Surg 2007;204:681–696
244. McGee D.C., Gould M.K. Preventing complications of central venous catheterization. N Engl J Med 2003; 348: 1123–1133
245. Karakitsos D., Labropoulos N., De Groot E. et al. Real-time ultrasound-guided catheterization of the internal jugular vein: a prospective comparison with the landmark technique in critical care patients. Crit Care 2006; 10: R162.
246. Leung J., Duffy M., Finckh A. Real-time ultrasonographically-guided internal jugular vein catheterization in the emergency department increases success rates and reduces complications: a randomized, prospective study. Ann Emerg Med 2006; 48: 540–547.
247. Hind D., Calvert N., McWilliams R. et al. Ultrasonic locating devices for central venous cannulation: meta-analysis. BMJ 2003; 327: 361
248. Schummer W., Sakr Y., Schummer C. Towards optimal central venous catheter tip position. In: Vincent J-L (ed). Intensive Care Medicine. Springer Verlag: Berlin, Germany, 2008, pp 581–590.
249. Vesely T.M. Central venous catheter tip position: a continuing controversy. J Vasc Interv Radiol 2003; 14: 527–534.
250. James M.T., Conley J., Tonelli M. et al. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann Intern Med 2008; 148: 596–605.
251. Jaffer Y., Selby N.M., Taal M.W. et al. A meta-analysis of hemodialysis catheter locking so-lutions in the prevention of catheter-related infection. Am J KidneyDis 2008; 51: 233– 241.
252. Labriola L., Crott R., Jadoul M. Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. Nephrol Dial Transplant 2008; 23: 1666–1672.
253. Yahav D., Rozen-Zvi B., Gafter-Gvili A. et al. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: sys-tematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis 2008; 47: 83–93.
254. Bagshaw S.M., Laupland K.B., Doig C.J. et al. Prognosis for long-term survival and renal re-covery in critically ill patients with severe acute renal failure: A population-based study. Crit Care 2005; 9: R700–R709.
255. Hsu C.Y., Chertow G.M., McCulloch C.E. et al. Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol 2009; 4:891–898.
256. Coca S.G., Singanamala S., Parikh C.R. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int2012;81(5):442-448.
257. Liano F., Tenorio M.T., Rodriguez-Mendiola N., Ponte B. Acute kidney injury as a risk factor for chronic kidney diseases in disadvantaged populations. Clin Nephrol 2010;74 (Suppl 1):S89-94.
258. Jain G., Jaimes E.A. Nicotine signaling and progression of chronic kidney disease in smok-ers.BiochemPharmacol2013;86(8):1215-1223.
259. Noborisaka Y. Smoking and chronic kidney disease in healthy populations. Nephrourol Mon2013;5(1):655-667.
260. Warmoth L., Regalado M.M., Simoni J. et al. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. Am J Med Sci 2005; 330(3): 111-119.
261. Hsu C.-Y., Lin F., Vittinghoff E., Shlipac M.G. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the UnitedState. J Am Soc Nephrol 2003; 14:2902-2907.
262. Krikken J.A., Lely A.T., Bakker S.J., Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007;71(3):260-265
263. Cheungpasitporn W., Thongprayoon C., Kittanamongkolchai W. et al. High alcohol consumption and the risk of renal damage: a systematic review and meta-analysis. QJM 2015; 108 (7):539-548.
264. Harris P.S., Roy S.R., Coughlan C. et al. Chronic ethanol consumption induces mitochondrial protein acetylation and oxidative stress in the kidney. Redox Biol 2015;6:33-40.
265. Okamura D.M., Pennathur S. The balance of powers: redox regulation of fibrogenic pathways in kidney injury. Redox Biol 2015;6:495-504.
266. Rodrigo R., Miranda A., Vergara L. Modulation of endogenous antioxidant system by wine polyphenols in human disease. Clin Chim Acta 2011;412(5-6):410-424
267. Смирнов А.В., Румянцев А.Ш.Реабилитация больных на гемодиализе: руководство для врачей.-М: СИМК, 2018:208
268. Malhotra R, Kashani K.B., Macedo E. et al. A risk prediction score for acute kidney injury in the intensive care unit, Nephrology Dialysis Transplantation, 2017; 32(5):814-822
269. Chawla L.S., Davison D.L., Brasha-Mitchell E. et al. Development and Standardization of a Furosemide Stress Test to Predict the Severity of Acute Kidney Injury. Crit Care 2013;17, R207
270. Авдошина С.В., Ефремовцева М.А., Виллевальде С.В., Кобалава Ж.Д. Оценка риска развития острого повреждения почек у больных с острой сердечно-сосудистой патологией без инвазивного вмешательства. Кардиология. 2019;59(12S):46-56.
271. Mehran R., Aymong E.D., Nikolsky E. et al. A Simple Risk Score for Prediction of Contrast-Induced Nephropathy After Percuta-neous Coronary Intervention J Am Coll Cardiol 2004;44:1393-1399.
272. Singer M, Deutschman CS, Seymour CW et al: The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801–810
273. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemor-rhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395-401.

ПРИЛОЖЕНИЯ